Neflamapimod

Drug Profile

Neflamapimod

Alternative Names: VX-745

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EIP Pharma; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Antidementias; Pyridazines; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis; Stroke

Most Recent Events

  • 16 Aug 2017 Neflamapimod is still at phase II development stage for Alzheimer's disease in USA and Netherlands (EIP Pharma website, August 2017)
  • 16 Dec 2016 Biomarkers information updated
  • 16 Nov 2016 EIP Pharma completes a phase II trial in Alzheimer's disease in the Netherlands (NCT02423122)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top